Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

Abstract Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Pediatric Infectious Diseases Society 2021-03, Vol.10 (2), p.201-204
Main Authors: Krogstad, Paul, Samson, Pearl, Acosta, Edward P, Moye, Jack, Townley, Ellen, Bradford, Sarah, Brown, Emily, Denson, Kayla, Graham, Bobbie, Hovind, Laura, Sise, Thucuma, Teppler, Hedy, Mathiba, Sisinyana Ruth, Fairlie, Lee, Winckler, Jana L, Slade, Gretchen, Meyers, Tammy
Format: Article
Language:English
Subjects:
Anti-HIV Agents - therapeutic use
Brief Reports
Child
HIV
HIV Infections - drug therapy
Humans
Raltegravir Potassium - adverse effects
Rifampin - adverse effects
Tuberculosis - complications
Tuberculosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to
ISSN:2048-7207
2048-7193
2048-7207
DOI:10.1093/jpids/piaa039